P359: IMPROVED OVERALL SURVIVAL AND MRD CLEARANCE WITH BLINATUMOMAB VS CHEMOTHERAPY AS PRE-TRANSPLANT CONSOLIDATION IN PEDIATRIC HIGH-RISK FIRST-RELAPSE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)

MLA

F. Locatelli, et al. “P359: Improved Overall Survival and Mrd Clearance with Blinatumomab Vs Chemotherapy as Pre-Transplant Consolidation in Pediatric High-Risk First-Relapse B-Cell Precursor Acute Lymphoblastic Leukemia (B-All).” HemaSphere, vol. 6, June 2022, pp. 259–60. EBSCOhost, https://doi.org/10.1097/01.HS9.0000844324.04051.5b.

APA

F. Locatelli, G. Zugmaier, C. Rizzari, J. Morris, B. Gruhn, T. Klingebiel, R. Parasole, C. Linderkamp, C. Flotho, A. Petit, C. Micalizzi, Y. Zeng, R. Desai, W. Kormany, C. Eckert, A. Möricke, M. Sartor, O. Hrusak, C. Peters, … A. von Stackelberg. (2022). P359: Improved Overall Survival and Mrd Clearance with Blinatumomab Vs Chemotherapy as Pre-Transplant Consolidation in Pediatric High-Risk First-Relapse B-Cell Precursor Acute Lymphoblastic Leukemia (B-All). HemaSphere, 6, 259–260. https://doi.org/10.1097/01.HS9.0000844324.04051.5b

Chicago

F. Locatelli, G. Zugmaier, C. Rizzari, J. Morris, B. Gruhn, T. Klingebiel, R. Parasole, et al. 2022. “P359: Improved Overall Survival and Mrd Clearance with Blinatumomab Vs Chemotherapy as Pre-Transplant Consolidation in Pediatric High-Risk First-Relapse B-Cell Precursor Acute Lymphoblastic Leukemia (B-All).” HemaSphere 6 (June): 259–60. doi:10.1097/01.HS9.0000844324.04051.5b.